Autism Spectrum Disorder Treatment Market Is Projected To Grow Robustly By 2030
Autism Spectrum Disorder Treatment Industry The global autism spectrum disorder treatment market size is expected to reach USD 3.28 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 6.1% from 2023 to 2030. Many of the experimental autism spectrum disorder (ASD) drugs in the academic studies and pharma pipeline are assessing important theories about how the genetic fingerprint and brain contribute to the development of autism. Some of the pipeline drugs include AB-2004 & AB-2004 PTR by Axial Therapeutics, Inc., Zygel by Zynerba Pharmaceuticals, Inc., and INP105 (Olanzapine) by Impel Pharmaceuticals Inc. In July 2022, Impel Pharmaceuticals Inc. initiated the first patient dose in phase 2a study evaluating INP-105 to treat acute agitation in adolescents with autism spectrum disorder (ASD). The company uses its Precision Olfactory Delivery (POD) technology to deliver medicine to the upper nasal part and increase the absorp...